Orciprenaline sulphate (Alupent): withdrawal from UK market after a risk-benefit analysis

01 November 2009

Orciprenaline sulphate (Alupent Syrup) is a medicine used to treat airway obstruction in conditions such as asthma. 

A recent safety review has shown that the benefits of orciprenaline sulphate no longer outweigh its risks. Therefore this medicine will be withdrawn from the market during 2010.

This safety update has also been highlighted in the November 2009 issue of Drug Safety Update (page 6)PDF file (opens in new window) (225Kb).

This report presents the evidence that was available when the regulatory decision was made, showing a ‘snapshot’ of the clinical landscape at the time. However, any advice in this report remains current unless it is superseded by a more recent report (where relevant, this is indicated).

Page last modified: 11 February 2016